Biohaven Current Ratio 2016-2023 | BHVN
Biohaven current ratio from 2016 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Biohaven Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2023-03-31 |
$0.54B |
$0.11B |
4.78 |
| 2022-12-31 |
$0.59B |
$0.09B |
6.52 |
| 2022-09-30 |
$0.08B |
$0.03B |
2.83 |
| 2022-06-30 |
$1.17B |
$0.67B |
1.75 |
| 2022-03-31 |
$1.17B |
$0.58B |
2.03 |
| 2021-12-31 |
$0.10B |
$0.04B |
2.26 |
| 2021-09-30 |
$0.94B |
$0.46B |
2.04 |
| 2021-06-30 |
$0.67B |
$0.40B |
1.67 |
| 2021-03-31 |
$0.90B |
$0.40B |
2.28 |
| 2020-12-31 |
$0.60B |
$0.28B |
2.17 |
| 2020-09-30 |
$0.71B |
$0.22B |
3.26 |
| 2020-06-30 |
$0.36B |
$0.17B |
2.18 |
| 2020-03-31 |
$0.47B |
$0.12B |
3.89 |
| 2019-12-31 |
$0.00B |
|
0.00 |
| 2019-09-30 |
$0.42B |
$0.05B |
8.96 |
| 2019-06-30 |
$0.47B |
$0.05B |
10.62 |
| 2019-03-31 |
$0.23B |
$0.02B |
9.60 |
| 2018-12-31 |
$0.27B |
$0.02B |
13.94 |
| 2018-09-30 |
$0.18B |
$0.02B |
11.99 |
| 2018-06-30 |
$0.23B |
$0.01B |
17.84 |
| 2018-03-31 |
$0.12B |
$0.02B |
6.80 |
| 2017-12-31 |
$0.14B |
$0.01B |
14.49 |
| 2017-09-30 |
$0.18B |
$0.02B |
8.12 |
| 2017-06-30 |
$0.21B |
$0.02B |
11.91 |
| 2017-03-31 |
$0.05B |
$0.02B |
3.44 |
| 2016-12-31 |
$0.02B |
$0.01B |
3.03 |
| 2016-09-30 |
$0.00B |
|
0.00 |
| 2016-06-30 |
$0.00B |
|
0.00 |
| 2016-03-31 |
$0.00B |
|
0.00 |
| 2015-12-31 |
$0.00B |
$0.00B |
5.74 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.477B |
$0.463B |
|
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
|
